Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 7 February

Jessica Amir
February 7, 2020

Reporting season: Mirvac results

Jessica Amir
February 6, 2020

Morning Bell 6 February

Jessica Amir
February 6, 2020

Morning Bell 5 February

Jessica Amir
February 5, 2020

Morning Bell 4 February

Jessica Amir
February 4, 2020

Morning Bell 3 February

Jessica Amir
February 3, 2020

January Market Overview

Jessica Amir
January 31, 2020

Morning Bell 31 January

Jessica Amir
January 31, 2020

Morning Bell 29 January

Jessica Amir
January 29, 2020

Morning Bell 28 January

Jessica Amir
January 28, 2020